Deferoxamine, the first FDA-approved drug in 1968 (Parker et al., 2023), is administered via intravenous (IV) or intramuscular (IM) injection due to its poor oral bioavailability, which is one of the most significant limitations of the DFO treatment ( A = 4 10 16 ) allows it to be the standard of care for acute iron toxicity for decades (Maggio et al., 2011)
Liu, T., Liu, Y., Zhao, X., Zhang, L., Wang, W., Bai, D., Liao, Y., Wang, Z., Wang, M., & Zhang, J
You wont know which
24-pack case contains 8.4oz cans
The role of FIM for weight management, including as a potential adjunctive therapy to GLP-1 use, is an area of growing interest and investigation
A., Mallone, R., Kent, S